Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01010
|
|||||
| Drug Name |
Epinastine
|
|||||
| Synonyms |
(+-)-Epinastine; 3-Amino-9,13b-dihydro-1H-dibenz(c,f)imidazo(1,5-a)azepine; 3-amino-9,13b-dihydro-1H-benz(c,f)imidazo(1,5a)azepine; 9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-amine; Elestat (TN); Epinastina; Epinastina [Spanish]; Epinastine (INN); Epinastine [INN]; Epinastinum; Epinastinum [Latin]; Purivist; Purivist (TN); Relestat (TN); WAL 80; WAL 801; WAL 801CL; WAL-80 Cl
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Cardiovascular disorder [ICD11: BA00-BE2Z] | Approved | [1] | |||
| Therapeutic Class |
Antihistamines
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C16H15N3
|
|||||
| Canonical SMILES |
C1C2C3=CC=CC=C3CC4=CC=CC=C4N2C(=N1)N
|
|||||
| InChI |
InChI=1S/C16H15N3/c17-16-18-10-15-13-7-3-1-5-11(13)9-12-6-2-4-8-14(12)19(15)16/h1-8,15H,9-10H2,(H2,17,18)
|
|||||
| InChIKey |
WHWZLSFABNNENI-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 80012-43-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 249.31 | Topological Polar Surface Area | 41.6 | ||
| Heavy Atom Count | 19 | Rotatable Bond Count | 0 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 1 | |||
| XLogP |
3.5
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
ChEBI:51037
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Epinastine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Influx and efflux transport of H1-antagonist epinastine across the blood-brain barrier. Drug Metab Dispos. 2004 May;32(5):519-24. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.